Desipramine clearance in children and adolescents: Absence of effect of development and gender

Journal of the American Academy of Child and Adolescent Psychiatry

Volumn 38, Issue 1, 1999, Pages 79-85

  Cohen, Louise Glassner ^a,b   Biederman, Joseph ^a,b   Wilens, Timothy E ^a,b   Spencer, Thomas J ^a,b   Mick, Eric ^a   Faraone, Stephen V ^a,b   Prince, Jefferson ^a,b   Flood, James G ^a,b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Desipramine; Gender; Pharmacokinetics

Indexed keywords

DESIPRAMINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADOLESCENT; ARTICLE; CHILD; CHILD PSYCHIATRY; CLINICAL TRIAL; DEPRESSION; DRUG CLEARANCE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; PRIORITY JOURNAL; PSYCHOPHARMACOTHERAPY; SEX DIFFERENCE;

EID: 0032895416     PISSN: 08908567     EISSN: None     Source Type: Journal    
DOI: 10.1097/00004583-199901000-00023     Document Type: Article

References (68)

1. Ambrosini PJ, Bianchi MD, Rabinovich H, Elia J (1993), Antidepressant treatments in children and adolescents, II: anxiety, physical and behavioral disorders. J Am Acad Child Adolesc Psychiatry 32:483-493
2. Baldessarini RJ (1996), Drugs and the treatment of psychiatric disorders: antimanic and antidepressant agents. In: Goodman and Gilman's The Pharmacologic Basis of Therapeutics, 9th ed, Harden W, Rudin W, Molinoff PB, Rall T, eds. New York McGraw-Hill, pp 431-459
3. Bertz RJ, Granneman GR (1997), Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions. Clin Pharmacokinet 32:210-258
4. Biederman J (1991), Clinical comment: sudden death in children treated with a tricyclic antidepressant. J. Am Acad Child Adolesc Psychiatry 30:495-497
5. Biederman J, Baldessarini R, Wright V, Knee D, Harmatz J (1989a), A double-blind placebo controlled study of desipramine in the treatment of attention deficit disorder, I: efficacy. J Am Acad Child Adolesc Psychiatry 28:777-784
6. Biederman J, Baldessarini RJ, Goldblatt A, Lapey KA, Doyle A, Hesslein PS (1993), A naturalistic study of 24-hour electrocardiographic findings in children and adolescents treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:805-813
7. Biederman J, Baldessarini RJ, Wright V, Knee D, Harmatz JS, Goldblatt A (1989b), A double-blind placebo controlled study of desipramine in the treatment of ADD, II: serum drug levels and cardiovascular findings. J Am Acad Child Adolesc Psychiatry 28:903-911
8. Biederman J, Faraone SV, Baldessarini RJ et al. (1997), Predicting desipramine levels in children and adolescents: a naturalistic clinical study. J Am Acad Child Adolesc Psychiatry 36:384-389
9. Bloch M, Schwatzman Y, Bonne O, Lerer B (1997), Concurrent treatment of nonresistant major depression with desipramine and lithium: a double-blind placebo controlled study. J Clin Psychopharmacol 17:44-48
10. Brasíc JR, Barnett JY, Sheitimn BB, Tsaltas MO (1997), Adverse effects of clomipramine (letter). J Am Acad Child Adolesc Psychiatry 36:1165-1166
11. Brosen K, Gram LF (1988), First-pass metabolism of imipramine and desipramine: impact of sparteine oxidation phenotype. Clin Pharmacol Ther 43:400-406
12. Brosen K, Klysner R, Gram LF, Otton SV, Bech P, Bertilsson L (1986a), Steady-state concentrations of imipramine and its metabolites in relation to the sparteine/debrisoquine polymorphism. Eur J Clin Pharmacol 30:679-684
13. Brosen K, Otton SV, Gram LF (1986b), Imipramine demethylation and hydroxylation: impact of the sparteine oxidation phenotype. Clin Pharmacol Ther 40:543-549
14. Bruun RD (1988), Subtle and unrecognized side effects of neuroleptic treatment in children with Tourette's disorder. Am J Psychiatry 145:621-624
15. Ciraulo DA, Barnhill JG, Jaffe JH (1988), Clinical pharmacokinetics of imipramine and desipramine in alcoholics and normal volunteers. Clin Pharmacol Ther 43:509-518
16. Dahl ML, Iselius L, Alm C et al. (1993), Polymorphic 2-hydroxylation of desipramine: a population and family study. Eur J Clin Pharmacol 44:445-450
17. Dell RD, Hein K, Ramakrishnan R, Puig-Antich J, Cooper T (1990), Model for the kinetics of imipramine and its metabolites in adolescents. Ther Drug Monit 12:450-459
18. Delgado LF, Pferferman A, Dirceu S, Naspitz CK (1998), Evaluation of the potential cardiotoxicity of the antihistamines terfenadine, astemizole, loratadine, and cetirizine in atopic children. Ann Allergy Asthma Immunol 80:333-337
19. de Montigny C, Cournoyer G, Morissette R, Langolois R, Caille G (1983), Lithium carbonate addition in tricyclic antidepressant-resistant unipolar depression. Arch Gen Psychiatry 40:1327-1334
20. Donnelly M, Zametkin AJ, Rapoport JL et al. (1986), Treatment of childhood hyperactivity with desipramine: plasma drug concentration, cardiovascular effects, plasma and urinary catecholamine levels and clinical response. Clin Pharmacol Ther 39:72-81
21. Efron D, Jarman F, Barker M (1997), Side effects of methylphenidate in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 100:662-666
22. Evans WE, Relling MV, Petros WP, Meyer WH, Miro J, Crom WR (1989), Dextromethorphan and caffeine as probes for simultaneous determination of debrisoquin-oxidation and N-acerylation phenotypes in children. Clin Pharmacol Ther 45:568-573
23. Feeney DJ, Klykylo WM (1997), Medication-induced seizures (letter). J Am Acad Child Adolesc Psychiatry 36:1018-1019
24. Food and Drug Administration (1997), Regulations requiring manufacturers to assess the safety and effectiveness of new drugs and biological products in pediatric patients. Code of Federal Regulations Title 21 Parts 201, 213, 314, and 601 (Docket No. 97N-0165)
25. Garfinkel BD, Wender PH, Sloman L, O'Neill I (1983), Tricyclic antidepressant and methylphenidate treatment of attention deficit disorder in children. J Am Acad Child Psychiatry 22:343-348
26. Gelman CR, Rumack BH, Sayre NK, eds (1998), DRUGDEX® System. Englewood, CO: MICROMEDEX Inc
27. Gibaldi M, Perrier D (1982), Pharmacokinetics, 2nd ed. New York: Marcel Decker
28. Grubbs JH (1997), SSRI-induced mania (letter). J Am Acad Child Adolesc Psychiatry 36:445
29. Harris RZ, Benet LZ, Schwartz JB (1995), Gender effects in pharmacokinetics and pharmacodynamics. Drugs 50:222-239
30. Heimann SW, March JS (1996), SSRI-induced mania (letter). J Am Acad Child Adolesc Psychiatry 35:4
31. Heninger GR, Charney DS, Sternberg DE (1983), Lithium carbonate augmentation of antidepressant treatment. Arch Gen Psychiatry 40:1335-1342
32. Kando JC, Yonkers KA, Cole JO (1995), Gender as a risk factor for adverse events to medication. Drugs 50:1-6
33. King RA, Riddle MA, Chappell PB et al. (1991), Emergence of self-destructive phenomena in children and adolescents during fluoxetine treatment. J Am Acad Child Adolesc Psychiatry 30:179-186
34. Koyama E, Chiba K, Tani M, Ishizaki T (1997), Reappraisal of human CYP isoforms involved in imipramine N-demethylation and 2-hydroxylation: a study using microsomes obtained from putative extensive and poor metabolizers of S-mephenytoin and eleven recombinant human CYPs. J Pharmacol Exp Ther 281:1199-1210
35. Kutcher S, Boulos C, Ward B et al. (1994), Response to desipramine treatment in adolescent depression: a fixed-dose, placebo controlled trial. J Am Acad Child Adolesc Psychiatry 33:686-694
36. Leeder JS, Kearns GL (1997), Pharmacogenetics in pediatrics: implications for practice. Pediatr Clin North Am 44:55-77
37. Lennard MS (1993), Genetically determined adverse drug reactions involving metabolism. Drug Saf 9:60-77
38. Madsen H, Rasmussen BB, Brosen K (1997), Imipramine demethylation in vivo: impact of CYP1A2, CYP2C19, and CYP3A4. Clin Pharmacol Ther 61:319-324
39. May DG (1994), Genetic differences in drug disposition. J Clin Pharmacol 34:881-897
40. Miesche KJ, Musa MN (1994), On mixtures of three normal populations caused by monogenic inheritance: application to desipramine metabolism. J Psychiatr Neurosci 19:295-300
41. Milsap RL, Hill MR, Szefler S (1992), Special pharmacokinetic considerations in children. In: Applied Pharmacokinctics: Principles of Therapeutic Drug Monitoring, Evans WE, Schentag JJ, Jusko WJ, eds. Vancouver, Ganada: Applied Therapeutics, pp: 10-1-10-32
42. Musa MN, Miesche KJ (1994), Pharmacogenetics of desipramine metabolism. Int J Clin Pharmacol Ther 32:126-130
43. Oldroyd J (1997), Paroxetine-induced mania (letter). J Am Acad Child Adolesc Psychiatry 36:721-722
44. Pataki CS, Carlson GA, Kelly KK, Rapport MD, Biancaniello TM (1993), Side effects of methylphenidate and desipramine alone and in combination in children. J Am Acad Child Adolesc Psychiatry 32:1065-1072
45. Peck CC, Barr WH, Benet LZ et al. (1992), Opportunities for integration of pharmacokinetics, pharmacodynamics, and toxicokinetics in rational drug development. Clin Pharmacol Ther 51:465-473
46. Perel JM, Black N, Wharton RN (1969), Inhibition of imipramine metabolism by methylphenidate. Fed Proc 28:418
47. Pollack S, Lieberman J, Kleiner et al. (1993), High plasma clozapine levels in tardive dyskinesia. Psychopharmacol Bull 29:257-262
48. Preskorn SH, Weller EB, Weller RA (1982), Depression in children: relationship between plasma imipramine levels and response. J Clin Psychiatry 43:450-453
49. Puig-Antich J, Perel JM, Lupatkin W et al. (1987), Plasma levels of imipramine (IMI) and desmethylimipramine (DMI) and clinical response in prepubertal major depressive disorder. J Am Acad Child Adolesc Psychiatry 18:616-627
50. Puopolo PR, Volpicelli SA, Johnson D, Flood JG (1991), Emergency toxicology testing of basic drugs in serum by liquid chromatography with photodiode array detection. Clin Chem 37:2124-2130
51. Rapoport JL, Mikkelsen EJ, Zavadil A et al. (1980), Childhood enuresis, II: psychopathology, tricyclic concentration in plasma, and antienuretic effect. Arch Gen Psychiatry 37:1146-1152
52. Relling MV, Cherrie J, Schell MJ, Petros W, Meyer WH, Evans WE (1991), Lower prevalence of debrisoquin oxidative poor metabolizer phenotypes in American black versus white subjects. Clin Pharmacol Ther 50:308-313
53. Rodman JH (1994), Pharmacokinetic variability in the adolescent: implications of body size and organ function for dosage regimen design. J Adolesc Health 15:654-662
54. Rudorfer MV, Potter WZ (1987), Pharmacokinetics of antidepressants. In: Psychopharmacology: The Third Generation of Progress, Meltzer HY, ed. New York: Raven, pp 1353-1363
55. Sallee FR, Pollock FR (1990), Clinical pharmacokinetics of imipramine and desipramine. Clin Pharmacokinet 18:346-364
56. Samara E, Granneman R (1997), Role of population pharmacokinetics in drug development: a pharmaceutical industry perspective. Clin Pharmacokinet 32:294-312
57. Singer HS, Brown J, Quaskey S, Rosenberg LA, Mellitis ED, Denckla MB (1995), The treatment of attention deficit hyperactivity disorder in Tourette's syndrome: a double-blind placebo controlled study with clonidine and desipramine. Pediatrics 95:74-81
58. Spencer T, Biederman J, Kerman K, Steingard R, Wilens T (1993), Desipramine treatment of children with attention deficit hyperactivity disorder and tic disorder or Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 32:354-360
59. Szymanski S, Lieberman J, Pollack S et al. (1996), Gender differences in neuroleptic nonresponsive clozapine treated schizophrenics. Biol Psychiatry 39:249-254
60. Varley CK, McClellan J (1997), Case study: two additional sudden deaths with tricyclic antidepressants. J Am Acad Child Adolesc Psychiatry 36:390-393
61. Vitiello B, Jensen PS (1997), Medication development and testing in children and adolescents: current problems, future directions. Arch Gen Psychiatry 54:871-876
62. Wharton RN, Perel JM, Dayton PG, Malitz S (1971), A potential clinical use for methylphenidate with tricyclic antidepressants. Am J Psychiatry 127:1619-1625
63. Wilens TE, Biederman J, Baldessarini RJ et al. (1996), Cardiovascular effects of therapeutic doses of tricyclic antidepressants in children and adolescents. J Am Acad Child Adolesc Psychiatry 35:1491-1501
64. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG (1992), Developmental changes in serum concentrations of desipramine and 2-hydroxydesipramine during treatment with desipramine. J Am Acad Child Adolesc Psychiatry 31:691-698
65. Wilens TE, Biederman J, Baldessarini RJ, Puopolo PR, Flood JG (1993a), Electrocardiographic effects of desipramine and 2-hydroxydesipramine in children, adolescents, and adults treated with desipramine. J Am Acad Child Adolesc Psychiatry 32:798-804
66. Wilens TE, Biederman J, Geist DE, Steingard R, Spencer T (1993b), Nortriptyline in the treatment of ADHD: a chart review of 58 cases. J Am Acad Child Adolesc Psychiatry 32:343-349
67. Woosley RL, Chen Y, Freiman JP, Gillis RA (1993), Mechanism of the cardiotoxic actions of terfenadine. JAMA 269:1532-1536
68. Yonkers KA, Kando JC, Cole JO, Blumenthal S (1992), Gender differences in pharmacokinetics and pharmacodynamics of psychotropic medication. Am J Psychiatry 149:587-595